Vigabatrin
Active ingredient: Vigabatrin
In short: Vigabatrin for oral solution is indicated as adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss .
What is Vigabatrin used for?
Vigabatrin for oral solution is indicated as adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss . Vigabatrin for oral solution is not indicated as a first line agent for complex partial seizures.
Vigabatrin for oral solution is indicated as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss .
âš Boxed warning (FDA's strongest warning)
Vigabatrin
can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability. In some cases,
vigabatrin
also can damage the central retina and may decrease visual acuity .
The onset of vision loss from
vigabatrin
is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years.
Symptoms of vision loss from
vigabatrin
are unlikely to be recognized by patients or caregivers before vision loss is severe. Vision loss of milder severity, while often unrecognized by the patient or caregiver, can still adversely affect function.
The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss.
Vision assessment is recommended at baseline (no later than 4 weeks after starting
vigabatrin
), at least every 3 months during therapy, and about 3 to 6 months after the discontinuation of therapy.
Once detected, vision loss due to
vigabatrin
is not reversible. It is expected that, even with frequent monitoring, some patients will develop severe vision loss.
Consider drug discontinuation, balancing benefit and risk, if vision loss is documented.
Risk of new or worsening vision loss continues as long as
vigabatrin
is used. It is possible that vision loss can worsen despite discontinuation of
vigabatrin
. …
Vigabatrin dosage
Dosing
Use the lowest dosage and shortest exposure to vigabatrin for oral solution consistent with clinical objectives .
The vigabatrin for oral solution dosing regimen depends on the indication, age group, weight, and dosage form (tablets or for oral solution) . Patients with impaired renal function require dose adjustment .
Monitoring of vigabatrin plasma concentrations to optimize therapy is not helpful.
Administration
Vigabatrin for oral solution is given orally with or without food.
Vigabatrin for oral solution should be mixed with water prior to administration . A calibrated measuring device is recommended to measure and deliver the prescribed dose accurately. A household teaspoon or tablespoon is not an adequate measuring device.
If a decision is made to discontinue vigabatrin for oral solution, the dose should be gradually reduced .
Adults (Patients 17 Years of Age and Older)
Treatment should be initiated at 1,000 mg/day (500 mg twice daily). Total daily dose may be increased in 500 mg increments at weekly intervals, depending on response. The recommended dose of vigabatrin for oral solution in adults is 3,000 mg/day (1,500 mg twice daily). A 6,000 mg/day dose has not been shown to confer additional benefit compared to the 3,000 mg/day dose and is associated with an increased incidence of adverse events.
In controlled clinical studies in adults with complex partial seizures, vigabatrin for oral solution was tapered by decreasing the daily dose 1,000 mg/day on a weekly basis until discontinued .
Pediatric (Patients 2 to 16 Years of Age)
The recommended dosage is based on body weight and administered as two divided doses, as shown in Table 1. The dosage may be increased in weekly intervals to the total daily maintenance dosage, depending on response.
Pediatric patients weighing more than 60 kg should be dosed according to adult recommendations.
Table 1. CPS Dosing Recommendations for Pediatric Patients Weighing 10 kg up to 60 kg†â€
Body Weight
[kg] | Total Daily*
Starting Dose
[mg/day] | Total Daily*
Maintenance Doseâ€
[mg/day]
10 kg to 15 kg | 350 mg | 1050 mg
Greater than 15 kg to 20 kg | 450 mg | 1300 mg
Greater than 20 kg to 25 kg | 500 mg | 1500 mg
Greater than 25 kg to 60 kg | 500 mg | 2000 mg
*Administered in two divided doses
†Maintenance dose is based on 3,000 mg/day adult-equivalent dose
††Patients weighing more than 60 kg should be dosed according to adult recommendations
In patients with refractory complex partial seizures, vigabatrin for oral solution should be withdrawn if a substantial clinical benefit is not observed within 3 months of initiating treatment. If, in the clinical judgment of the prescriber, evidence of treatment failure becomes obvious earlier than 3 months, treatment should be discontinued at that time . …
How to take Vigabatrin — instructions & advice from the label
Advise patients and caregivers to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Administration Instructions for
Vigabatrin
for oral solution
Physicians should confirm that caregiver(s) understand how to mix vigabatrin for oral solution and to administer the correct dose to their infants and pediatric patients .
Permanent Vision Loss
Inform patients and caregivers of the risk of permanent vision loss, particularly loss of peripheral vision, from vigabatrin for oral solution, and the need for monitoring vision .
Monitoring of vision, including assessment of visual fields and visual acuity, is recommended at baseline (no later than 4 weeks after starting vigabatrin for oral solution), at least every 3 months while on therapy, and about 3-6 months after discontinuation of therapy. In patients for whom vision testing is not possible, treatment may continue without recommended testing according to clinical judgment with appropriate patient or caregiver counseling. …
Warnings & precautions
Do not take this medicine if: None.
Vigabatrin can cause permanent vision loss. Because of this risk and because, when it is effective, vigabatrin provides an observable symptomatic benefit; patient response and continued need for treatment should be periodically assessed.
Based upon adult studies, 30 percent or more of patients can be affected with bilateral concentric visual field constriction ranging in severity from mild to severe. Severe cases may be characterized by tunnel vision to within 10 degrees of visual fixation, which can result in disability. In some cases, vigabatrin also can damage the central retina and may decrease visual acuity. Symptoms of vision loss from vigabatrin are unlikely to be recognized by patients or caregivers before vision loss is severe. Vision loss of milder severity, while often unrecognized by the patient or caregiver, can still adversely affect function.
Because assessing vision may be difficult in infants and children, the frequency and extent of vision loss is poorly characterized in these patients. For this reason, the understanding of the risk is primarily based on the adult experience. The possibility that vision loss from vigabatrin may be more common, more severe, or have more severe functional consequences in infants and children than in adults cannot be excluded.
The onset of vision loss from vigabatrin is unpredictable and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years.
The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss.
In patients with refractory complex partial seizures, vigabatrin should be withdrawn if a substantial clinical benefit is not observed within 3 months of initiating treatment. …
Vigabatrin side effects
The following serious and otherwise important adverse reactions are described elsewhere in labeling:
Permanent Vision Loss
Magnetic Resonance Imaging (MRI) Abnormalities in Infants
Neurotoxicity
Suicidal Behavior and Ideation
Withdrawal of Antiepileptic Drugs (AEDs)
Anemia
Somnolence and Fatigue
Peripheral Neuropathy
Weight Gain
Edema
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In U.S. and primary non-U.S. clinical studies of 4,079 vigabatrin-treated patients, the most common (≥5%) adverse reactions associated with the use of vigabatrin in combination with other AEDs were headache, somnolence, fatigue, dizziness, convulsion, nasopharyngitis, weight gain, upper respiratory tract infection, visual field defect, depression, tremor, nystagmus, nausea, diarrhea, memory impairment, insomnia, irritability, abnormal coordination, blurred vision, diplopia, vomiting, influenza, pyrexia, and rash.
The adverse reactions most commonly associated with vigabatrin treatment discontinuation in ≥1% of patients were convulsion and depression. …
Drug interactions
Phenytoin
Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since vigabatrin may cause a moderate reduction in total phenytoin plasma levels .
Clonazepam
Vigabatrin may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions .
Other AEDs
There are no clinically significant pharmacokinetic interactions between vigabatrin and either phenobarbital or sodium valproate. Based on population pharmacokinetics, carbamazepine, clorazepate, primidone, and sodium valproate appear to have no effect on plasma concentrations of vigabatrin .
Vigabatrin is unlikely to affect the efficacy of steroid oral contraceptives .
Vigabatrin decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury.
Vigabatrin may increase the amount of amino acids in the urine, possibly leading to a false positive test for certain rare genetic metabolic diseases (e.g., alpha aminoadipic aciduria).
About this medicine
Vigabatrin for oral solution, USP is an oral antiepileptic drug and is available as a white to off-white powder for oral solution in packets of 500 mg.
The chemical name of vigabatrin, USP, a racemate consisting of two enantiomers, is (±) 4-amino-5-hexenoic acid. The molecular formula is C6H11NO2 and the molecular weight is 129.16. It has the following structural formula:
Vigabatrin, USP is a white or almost white powder which is freely soluble in water, slightly soluble in methanol, practically insoluble in methylene chloride. The pH of a 1% aqueous solution is about 6.9. The n-octanol/water partition coefficient of vigabatrin, USP is about 0.011 (log P=-1.96) at physiologic pH. Vigabatrin, USP melts with decomposition in a 3-degree range within the temperature interval of 171°C to 176°C. The dissociation constants (pKa) of vigabatrin, USP are 4 and 9.7 at room temperature (25°C).
Vigabatrin for oral solution, USP is available as a white to off-white powder. Each packet contains 500 mg of vigabatrin, USP. The inactive ingredient is povidone. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e7cbc0a5-8c28-4451-9176-b608e228ba66. Read the full official label on DailyMed.
Related medicines
Gabapentin Lamotrigine Pregabalin Topiramate Levetiracetam Oxcarbazepine Carbamazepine Ciclopirox